73 results about "Lewy body" patented technology

Disclosed are compounds, and corresponding methods of treatment, that activate myocyte-specific enhancer factor 2 (MEF2) transcriptional activity that are therefore useful in treating deficits in MEF2C activity found in autism spectrum disorder (ASD), intellectual disability (ID), attention deficit and hyperactivity disorder (ADHD), and in diseases characterized by cognitive decline such as Alzheimer's disease (AD), Lewy body dementia (LED), Frontotemporal dementia (FTD), and other forms of dementia, as well as movement disorders such as Parkinson's disease (PD) and parkinsonism from other causes.

The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).

Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an α-synuclein binding domain operably linked to a protein transduction domain and a proteasomal targeting domain, wherein the α-synuclein binding domain is derived from a reversed sequence of β-synuclein. Other methods, as well as uses and compositions, are disclosed.

The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

Combination compositions of Compound 1 and fesoterodine for use in the treatment of neurological disorders, such as schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia, are described.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The invention discloses an application of 5-nitro-8-hydroxyquinoline in activation of a TMEM175 channel and a preparation method of the 5-nitro-8-hydroxyquinoline. The invention further discloses a method for activating the TMEM175 channel. The method comprises the step of using the 5-nitro-8-hydroxyquinoline, the pharmaceutically acceptable salt of the 5-nitro-8-hydroxyquinoline and / or the isotope derivative of the 5-nitro-8-hydroxyquinoline. According to the invention, the small molecule 5-nitro-8-hydroxyquinoline which specifically targets the TMEM175 channel and can activate the TMEM175 channel is screened, and the result proves that the 5-nitro-8-hydroxyquinoline can be used as a compound targeting the TMEM175 channel and is used for preparing medicines for treating neurodegenerative diseases, such as Parkinson's disease and / or Lewy body dementia.

The invention discloses ursodesoxycholic acid and amino acid conjugates (I), pharmaceutically acceptable salts thereof, a preparation method of the ursodesoxycholic acid and amino acid conjugates, a pharmaceutical composition of the ursodesoxycholic acid and amino acid conjugates and application of the ursodesoxycholic acid and amino acid conjugates in preparation of drugs for treating and / or preventing comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses an aminoamide alkyl thioester compound (I), pharmaceutically acceptable salts thereof, a preparation method of the aminoamide alkyl thioester compound, a pharmaceutical composition of the aminoamide alkyl thioester compound and application of the aminoamide alkyl thioester compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses an amide alkyl thiol ester compound (I) as well as a preparation method and a pharmaceutical composition thereof, and application of the amide alkyl thiol ester compound in preparation of drugs for treating and / or preventing diseases by resisting oxidative stress, inhibiting amyloid protein aggregation and resisting neuroinflammation. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

Diagnostic and therapeutic methods for neurodegenerative diseases. Are provided involving assaying abnormal proteins (hyperphosphorylated tau, α-synuclein, TDP-43) associated with neuronal turnover inhibition or promotion in patient samples. Abnormal protein expression and apoptotic activity are detected, aiding disease progression assessment. Therapeutically, a method is provided for treating neurodegenerative diseases, administering compounds promoting neuronal turnover or modulating proteins involved in the process. The invention extends to identifying suitable drugs, employing neuronal turnover induction, miRNA modulation, and protein activity inhibition or enhancement. The claims also encompass various species, tissues, and cultured cells. Furthermore, the invention is applicable to diverse neurodegenerative diseases with abnormal protein accumulation, presenting novel diagnostic and treatment approaches.

The invention is directed to immunological compositions of one or more peptides containing epitopes of PGN, LTA and LPS molecules that induce an immunological response in a mammal, and to multiple antibodies that bind to these epitopes. Immunological compositions and antibodies disclosed herein can be used in the treatment and / or prevention of human health disorders such as bacterial sepsis, inflammation, cancers, tumors, inflammatory diseases and disorders, and neurodegenerative disorders such as, but not limited to Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and / or limbic predominant age-related TDP-43 encephalopathy (LATE).

The novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are NLRP3 inhibitors and may be useful in the treatment, prevention, management, improvement, control, and suppression of NLRP3-mediated diseases. The compounds of the present invention may be useful in the treatment, prevention, or management of NLRP3-mediated diseases, disorders, and conditions such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, Lewy body dementia (LBD), and traumatic brain injury. (I)

Provided herein are compounds, pharmaceutical compositions, and methods of use for reducing the amount or activity of SNCA mRNA in a cell or subject, and in some instances, the amount of alpha-synuclein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful for ameliorating at least one symptom or marker of synucleinopathies. Such synucleinopathies include Parkinson's disease, Lewy body dementia (DLB), diffuse Lewy body disease, Parkinson's disease dementia (PDD), pure autonomic failure, multi-system atrophy (MSA), neurological Gaucher's disease, and Alzheimer's disease.

The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.

The present invention provides a method of treating neurodegenerative diseases. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate, or a nanocomplex having an outer shell comprising one or more polymer-flavonoid conjugates and optionally an inner shell comprising one or more flavonoid oligomer and a drug such as anti-CD3 or anti-CD33 encapsulated within the shells. The present method brings therapeutic effective materials through blood-brain barrier to treat neurodegenerative diseases. The present method is effective to treat neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and Huntington's disease.

The application relates to the technical field of medicines, and particularly discloses a use of (2,4-dichlorophenyl)methylsulfenyl methane amidine and salts thereof. Specifically, the application finds that (2,4-dichlorophenyl)methylsulfenyl methane amidine and its applicable medicinal derivatives can significantly enhance memory, improve the survival rate of neuron cells of patients or promote the regeneration of neuron processes of patients, and can be used for preparing medicines and health products for treating neurological diseases (such as Alzheimer's disease, vascular dementia or Lewy body dementia).

The invention belongs to the technical field of biological medicines, and particularly relates to new application of a DGAT inhibitor (including a DGAT1 inhibitor and a DGAT2 inhibitor) in delaying neuronal senescence and preventing or treating neurodegenerative diseases related to neuronal senescence. An in-vitro cell experiment verifies that the DGAT inhibitor can effectively delay the senescence process of neuronal cells, and the expression of senescence-related secretion phenotypes is reduced. On the basis, the DGAT inhibitor can be used for preparing medicines for preventing or treating various neuron senescence-related neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia and the like, and a new strategy and a medicine candidate are provided for intervening neuron senescence and preventing and treating the neurodegenerative diseases.

The present disclosure provides, among other things, human codon-optimized sequences encoding presenilin 1, and methods for using the sequences in gene therapy to treat neurodegenerative diseases including, but not limited to Alzheimer's disease, frontotemporal dementia, frontotemporal lobar degeneration, Pick's disease, Lewy body dementia, memory loss, and cognitive impairment including mild cognitive impairment (MCI).

The present disclosure provides, among other things, methods for using presenilin based gene therapy to treat neurodegenerative dementia including, but not limited to Alzheimers disease, frontotemporal dementia, frontotemporal lobar degeneration, Picks disease, Lewy body dementia, memory loss, and cognitive impairment including mild cognitive impairment (MCI).

The present invention provides a method of treating a neurodegenerative disease. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate or nanocomposite, the nanocomposites have an outer shell comprising one or more polymer-flavonoid conjugates and, optionally, an inner shell comprising one or more flavonoid oligomers, as well as drugs, such as anti-CD3 or anti-CD33, encapsulated within these shells. The methods of the invention allow therapeutically effective substances to pass through the blood-brain barrier to treat neurodegenerative diseases. The methods of the invention are effective in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and Huntington's disease.

The present invention discloses a method for constructing and using an animal model of dementia with Lewy bodies, and belongs to the technical field of animal model construction. The construction method comprises: obtaining a phosphatase and tensin homologous gene-induced kinase 1 gene knockout experimental animal A using gene editing technology, and crossbreeding with an Alzheimer's disease model experimental animal B simulating β-amyloid protein (Aβ) pathology, and screening offspring containing both Alzheimer's disease-related mutations and pink1 gene knockout. The model constructed by the present invention is to deposit β-amyloid protein on the basis of pink1 gene knockout, induce α-synuclein protein aggregation using β-amyloid plaques (Aβ), widely produce Lewy bodies in the cortex and hippocampus, simulate the occurrence and development process of DLB, and provide a reliable animal model for disease mechanism research and therapeutic drug screening and development.

The present invention provides a method of treating neurodegenerative diseases. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate, or a nanocomplex having an outer shell comprising one or more polymer-flavonoid conjugates and optionally an inner shell comprising one or more flavonoid oligomer and a drug such as anti-CD3 or anti-CD33 encapsulated within the shells. The present method brings therapeutic effective materials through blood-brain barrier to treat neurodegenerative diseases. The present method is effective to treat neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and Huntington's disease.

Disclosed herein are peptides, derivatives thereof, and salts thereof, as well as pharmaceutical compositions containing them, useful alone or in combination with other therapies for treating multifactorial neurological and other diseases. The pharmaceutical compositions may include the peptides, derivatives thereof, or salts thereof, where the peptides may include at least five consecutive amino acids having the general formula: EFGHI, or derivatives thereof, and the multifactorial neurological diseases may include Lewy body variant of Alzheimer's disease (LBVAD) or vascular dementia.

To provide compounds for effective treatment of diseases and disorders related to LRRK2, which are idiopathic PD, LRRK2 mutation associated PD (e.g., PD associated with one or more LRRK2 activated mutations), primary tauopathy (e.g., progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD)), Lewy body dementia, Crohn's disease, Hansen's disease (e.g., Hansen's disease associated with type 1 inflammatory reactions), and / or neuroinflammation, for example.SOLUTION: Provided are bifunctional compounds useful as modulators of leucine-rich repeat kinase 2 (LRRK2). Particularly, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.SELECTED DRAWING: None

This document describes a combination composition of compound 1 and fesoterodine for treating neurological disorders (e.g., schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive impairment in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia).

Disclosed are compounds of Formulas (I), (la), (lb), (II), (Ila), (III), (Illa), and (Illb), as well as pharmaceutical compositions thereof. The compounds can be used to improve proteostasis and enhance clearance of protein accumulation events by positively modulating the autophagy-lysosomal pathway, including augmenting the activity of cathepsin enzymes, and / or to treat neurological diseases, disorders and conditions, such as, but not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, mild cognitive impairment, frontotemporal dementia, amyotrophic lateral sclerosis, Lewy body dementias, chronic traumatic encephalopathy, traumatic brain injury, and α-synucleinopathies.

The invention provides application of an aminopyridine potassium channel inhibitor in inhibiting or reducing abnormal aggregation of alpha-synuclein or inhibiting or reducing formation of Lewy bodies or Lewy protrusions, and application of aminopyridine substances in treating dementia related to the Lewy bodies, such as Lewy body dementia or Parkinson's disease dementia.